The earnings call highlighted significant progress in Verrica Pharmaceuticals' financial position, YCANTH sales growth, and clinical pipeline advancements. However, challenges such as obsolete inventory costs, suboptimal revenue figures, and financial covenant concerns were also noted. Overall, the positive developments in fundraising, sales growth, and clinical progress were prominent.

Company Guidance -

Q2 2025

During the call, Verrica Pharmaceuticals provided guidance for their fiscal year 2024 and beyond, highlighting several key metrics and strategic developments. The company reported a sequential quarterly growth of 12.3% in YCANTH dispense applicator units, with 8,654 units in the fourth quarter of 2024, compared to 7,706 units in the previous quarter. This growth represents a 44.8% increase from the second quarter of 2024, which saw 5,975 units. Verrica also raised approximately $42 million in an equity follow-on offering in November and negotiated a waiver of a going concern covenant with OrbiMed. The company achieved a reduction in operating expenses by approximately 50% while maintaining prior sales levels and achieving positive growth. Looking forward, Verrica aims to advance its clinical pipeline, including a global Phase 3 trial for YCANTH in common warts, and continues to support partners in regulatory efforts in Japan. The company's financial position includes cash and cash equivalents of $46.3 million as of December 31, 2024, and they anticipate further growth and positive cash flow by the end of 2025.

Successful Fundraising and Improved Financial Position

Verrica Pharmaceuticals raised approximately $42 million in an equity follow-on offering in November 2024, strengthening their balance sheet and securing a waiver of going concern covenant from OrbiMed for the quarter and year ended December 31, 2024 and the first quarter of 2025.

Positive Growth in YCANTH Sales

YCANTH dispense applicator units increased by 12.3% in Q4 2024 compared to the prior quarter and by 44.8% compared to Q2 2024. The new commercialization strategy has led to increased productivity of sales representatives and a reduction in operating expenses by approximately 50%.

Progress in Clinical Pipeline

Advancement of YCANTH for common warts and the novel oncolytic peptide BP-315 for basal cell carcinoma, with minimal additional cash outlay. Positive preliminary results for BP-315 were presented, showing a calculated objective response rate of 97%.

Market Expansion and Product Accessibility

Introduction of a new single applicator configuration for YCANTH, which became commercially available to reduce acquisition costs for physicians and expand patient access. Enhanced distribution through specialty pharmacies.

Verrica Pharmaceuticals (VRCA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VRCA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-0.90 / -	-3.7	―	―	―
May 13, 2025	2025 (Q1)	-1.26 / -1.00	-4.4	77.27% (+3.40)	―
Mar 11, 2025	2024 (Q4)	-2.50 / -2.40	-5.3	54.72% (+2.90)	―
Nov 04, 2024	2024 (Q3)	-3.76 / -4.90	-5.4	9.26% (+0.50)	―	―
Aug 14, 2024	2024 (Q2)	-4.14 / -3.70	-2.4	-54.17% (-1.30)	―
May 13, 2024	2024 (Q1)	-4.47 / -4.40	-1.5	-193.33% (-2.90)	―
Feb 29, 2024	2023 (Q4)	-5.62 / -5.30	-1.4	-278.57% (-3.90)	―
Nov 09, 2023	2023 (Q3)	-3.61 / -5.40	0	―	―
Aug 08, 2023	2023 (Q2)	-2.10 / -2.40	-3.7	35.14% (+1.30)	―	―
May 09, 2023	2023 (Q1)	-1.91 / -1.50	-3.1	51.61% (+1.60)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VRCA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$5.50	$5.35	-2.73%
Mar 11, 2025	$6.48	$5.99	-7.56%
Nov 04, 2024	$14.30	$7.98	-44.20%
Aug 14, 2024	$52.70	$31.20	-40.80%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Verrica Pharmaceuticals (VRCA) report earnings?

Verrica Pharmaceuticals (VRCA) is schdueled to report earning on Aug 12, 2025, TBA (Confirmed).

What is Verrica Pharmaceuticals (VRCA) earnings time?

Verrica Pharmaceuticals (VRCA) earnings time is at Aug 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VRCA EPS forecast?

VRCA EPS forecast for the fiscal quarter 2025 (Q2) is -0.9.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing